7 January 2019 - The FDA plans to create a new office to improve the review of new medicines — one that will develop a standardised approach to using personalised medicine, digital data, and patients’ own reports, according to Commissioner Scott Gottlieb.

Gottlieb will outline the plan for the new 52-person group, called the Office of Drug Evaluation Science (ODES), as part of a talk at the annual J.P. Morgan Healthcare Conference on Tuesday. 

Because of the government shutdown, he will deliver the talk via videoconference. “We’re operating with limited staff and I’m needed here,” he said.

Read Stat News article